Rhenium NanoLiposomes receives Fast Track Designation from FDA for glioblastoma treatment

FDA has granted Rhenium NanoLiposomes Fast Track Designation for the treatment of patients with recurrent glioblastoma.

Plus Therapeutics Inc. sponsors Rhenium NanoLiposomes (RNL). RNL previously received orphan drug designation from the FDA for RNL for the treatment of patients with glioblastoma.

“With this designation in hand, we intend to move into cohort six of the trial, one key step closer to bringing forth a novel therapy for these patients,” Marc Hedrick, president and chief executive officer of Plus Therapeutics said in a statement.

RNL is being evaluated in the NIH/NCI-supported, multi-center ReSPECT phase I dose-finding clinical trial (NCT01906385). The ReSPECT trials’ data and safety monitoring board approved the Plus Therapeutics to proceed to cohort six of the trial, which includes increasing both the drug volume and radiation dose to 8.8 milliliters (mL) and 22.3 millicuries (mCi), respectively.

RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation, of up to 25 times greater concentration than currently used external beam radiation therapy, directly into the brain tumor for maximum effect.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

White House

Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed

W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and his team are expected to usher in starting next week.

January 17, 2025

Vol.51 No.02

By Paul Goldberg

Guest Editorial

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the inclusion of tissue biopsies in clinical trials.

January 17, 2025

Vol.51 No.02

By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer

ACS report: Cancer mortality continues to drop despite rising incidence in women

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men.

January 17, 2025

Vol.51 No.02

By Yiqing Wang

Guest Editorial

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history.

January 17, 2025

Vol.51 No.02

By Dan Theodorescu, Robert A. Figlin, Howard M. Sandler and Joan August

Clinical

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

January 17, 2025

Vol.51 No.02

By Jacquelyn Cobb

Clinical Trials & Tribulations

Chadi Nabhan: Why I wrote a book about cancer

Almost all of us who have practiced oncology for years have encountered situations where we have had to counsel caregivers and guide them throughout their loved ones’ journeys. We have faced patients who took complementary therapies to an extreme; some to a point where they wouldn’t share what they were taking for fear that we might demand they stop.

January 17, 2025

Vol.51 No.02

By Chadi Nabhan

Rhenium NanoLiposomes receives Fast Track Designation from FDA for glioblastoma treatment

YOU MAY BE INTERESTED IN

Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

ACS report: Cancer mortality continues to drop despite rising incidence in women

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

Chadi Nabhan: Why I wrote a book about cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Rhenium NanoLiposomes receives Fast Track Designation from FDA for glioblastoma treatment

YOU MAY BE INTERESTED IN

Rathmell steps down at NCI as Trump team considers candidates to replace herWafik El-Deiry, Harvey Risch have been interviewed

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

ACS report: Cancer mortality continues to drop despite rising incidence in women

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

Chadi Nabhan: Why I wrote a book about cancer

Never miss an issue!

Login

Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed